Cardiff Oncology, Nerviano settle onvansertib rights lawsuit, seek dismissal with prejudice

By Public Technologies
  • Cardiff Oncology reached a settlement with Nerviano Medical Sciences tied to litigation over global rights to onvansertib.
  • Both sides agreed to a full mutual release of claims in a U.S. District Court case in Southern District of California.
  • The parties plan to seek dismissal of all claims with prejudice under an amended 2017 exclusive license agreement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140830PRIMZONEFULLFEED9826162) on September 14, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk